News
Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...
The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
StockStory.org on MSN22h
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results